Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jun;396(6-7):737-47.
doi: 10.1515/hsz-2015-0129.

Preclinical Development of a C6-ceramide NanoLiposome, a Novel Sphingolipid Therapeutic

Review

Preclinical Development of a C6-ceramide NanoLiposome, a Novel Sphingolipid Therapeutic

Mark Kester et al. Biol Chem. .

Abstract

Despite the therapeutic potential of sphingolipids, the ability to develop this class of compounds as active pharmaceutical ingredients has been hampered by issues of solubility and delivery. Beyond these technical hurdles, significant challenges in completing the necessary preclinical studies to support regulatory review are necessary for commercialization. This review seeks to identify the obstacles and potential solutions in the translation of a novel liposomal technology from the academic bench to investigational new drug (IND) stage by discussing the preclinical development of the Ceramide NanoLiposome (CNL), which is currently being developed as an anticancer drug for the initial indication of hepatocellular carcinoma (HCC).

Similar articles

See all similar articles

Cited by 13 articles

See all "Cited by" articles

MeSH terms

Feedback